Voyageur Pharmaceuticals Ltd Total Assets
Voyageur Pharmaceuticals Ltd total assets. Based on the latest financial reports, Voyageur Pharmaceuticals Ltd (VM) holds total assets worth CA$3.11 Million CAD (≈ $2.25 Million USD) as of November 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Voyageur Pharmaceuticals Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of Voyageur Pharmaceuticals Ltd (2011–2025)
Total assets of Voyageur Pharmaceuticals Ltd from 2011 to 2025. This chart illustrates how Voyageur Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See VM stock price and chart for real-time trading data and today's change.
Voyageur Pharmaceuticals Ltd - Asset Composition Analysis
Voyageur Pharmaceuticals Ltd Total Assets Breakdown (November 2025)
Voyageur Pharmaceuticals Ltd total assets breakdown as of November 2025. Voyageur Pharmaceuticals Ltd's total assets of CA$3.11 Million consist of 19.2% current assets and 80.8% non-current assets. Explore Voyageur Pharmaceuticals Ltd (VM) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 8.6% |
| Accounts Receivable | CA$134.05K | 4.3% |
| Inventory | CA$49.17K | 1.6% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Voyageur Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Voyageur Pharmaceuticals Ltd's current assets represent 19.2% of total assets in 2025, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 8.6% of total assets in 2025, down from 76.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 4.3% of total assets.
Voyageur Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Voyageur Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Dezhan HealthCare Co Ltd
SHE:000813
|
China | CN¥4.77 Billion |
|
Chongqing Pharscin Pharmaceutical Co Ltd
SHE:002907
|
China | CN¥2.00 Billion |
Voyageur Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.33 | 0.17 | 0.03 |
| Quick Ratio | 0.30 | 0.14 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-1.22 Million | CA$-1.74 Million | CA$-884.80K |
Voyageur Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Voyageur Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.23 |
| Latest Market Cap to Assets Ratio | 4.99 |
| Asset Growth Rate (YoY) | 19.5% |
| Total Assets | CA$3.11 Million |
| Market Capitalization | $15.50 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Voyageur Pharmaceuticals Ltd's assets at a significant premium (4.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Voyageur Pharmaceuticals Ltd's assets grew by 19.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Voyageur Pharmaceuticals Ltd (2011–2025)
The table below shows the annual total assets of Voyageur Pharmaceuticals Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-11-30 | CA$3.11 Million ≈ $2.25 Million |
+19.50% |
| 2024-11-30 | CA$2.60 Million ≈ $1.88 Million |
+20.09% |
| 2023-11-30 | CA$2.16 Million ≈ $1.57 Million |
+3.26% |
| 2022-11-30 | CA$2.10 Million ≈ $1.52 Million |
-18.37% |
| 2021-11-30 | CA$2.57 Million ≈ $1.86 Million |
+101.29% |
| 2020-11-30 | CA$1.28 Million ≈ $922.45K |
-20.64% |
| 2019-11-30 | CA$1.61 Million ≈ $1.16 Million |
+26.87% |
| 2018-11-30 | CA$1.27 Million ≈ $916.14K |
+45.59% |
| 2017-11-30 | CA$869.88K ≈ $629.26K |
+22.64% |
| 2016-11-30 | CA$709.32K ≈ $513.11K |
+693.81% |
| 2015-11-30 | CA$89.36K ≈ $64.64K |
-44.15% |
| 2014-11-30 | CA$160.00K ≈ $115.75K |
-13.32% |
| 2013-11-30 | CA$184.60K ≈ $133.53K |
-24.60% |
| 2012-11-30 | CA$244.82K ≈ $177.10K |
+18.72% |
| 2011-11-30 | CA$206.21K ≈ $149.17K |
-- |
About Voyageur Pharmaceuticals Ltd
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The co… Read more